Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results

被引:160
|
作者
Carter, HB [1 ]
Walsh, PC
Landis, P
Epstein, JI
机构
[1] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Johns Hopkins Hosp,Dept Urol, Baltimore, MD 21218 USA
[2] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Johns Hopkins Hosp,Dept Pathol, Baltimore, MD USA
来源
JOURNAL OF UROLOGY | 2002年 / 167卷 / 03期
关键词
prostatic neoplasm; patient case management;
D O I
10.1016/S0022-5347(05)65271-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluate a strategy of expectant management for men with stage T1c prostate cancer. Materials and Methods: A total of 81 men (median age 65 years, range 52 to 72) with stage T1c prostate cancer who were thought to have small volume prostate cancer based on needle biopsy findings and prostate specific antigen (PSA) density were followed for more than 1 year with semiannual PSA and digital rectal examination, and annual prostate biopsies (median followup 23 months, range 12 to 58). A recommendation for treatment was made if disease progression was indicated by unfavorable followup needle biopsy findings (Gleason pattern 4 or 5, greater than 2 biopsy cores with cancer, greater than 50% involvement of any core with cancer). Curable disease was defined on pathological examination of radical prostatectomy specimens as 1) organ confined cancer of Gleason score 7 or less, 2) cancer with extraprostatic extension of Gleason score 7 (3 + 4) or less with negative margins, seminal vesicles and lymph nodes, or 3) cancer of Gleason score 6 or less regardless of margin status or extraprostatic extension if negative seminal vesicles and lymph nodes. Results: Of the 81 men 25 (31%) had progression of disease at followup. PSA density was statistically significantly higher (p = 0.01) and the percentage of free PSA was statistically significantly lower (p = 0.04) in men with compared to those without disease progression. Disease progression occurred in 22 of 39 men (56%) with every followup biopsy showing cancer compared to 3 of 42 (2%) men with 1 or more negative followup biopsies (p <0.001). Of the 25 men with progression 13 underwent radical prostatectomy and 12 of 13 (92%) had curable cancers. Conclusions: Expectant management with curative intent may be a reasonable alternative for carefully selected older men who are thought to have small volume cancers.
引用
收藏
页码:1231 / 1234
页数:4
相关论文
共 50 条
  • [41] Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer
    McIntosh, Chris
    Conroy, Leigh
    Tjong, Michael C.
    Craig, Tim
    Bayley, Andrew
    Catton, Charles
    Gospodarowicz, Mary
    Helou, Joelle
    Isfahanian, Naghmeh
    Kong, Vickie
    Lam, Tony
    Raman, Srinivas
    Warde, Padraig
    Chung, Peter
    Berlin, Alejandro
    Purdie, Thomas G.
    NATURE MEDICINE, 2021, 27 (06) : 999 - +
  • [42] Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer
    Chris McIntosh
    Leigh Conroy
    Michael C. Tjong
    Tim Craig
    Andrew Bayley
    Charles Catton
    Mary Gospodarowicz
    Joelle Helou
    Naghmeh Isfahanian
    Vickie Kong
    Tony Lam
    Srinivas Raman
    Padraig Warde
    Peter Chung
    Alejandro Berlin
    Thomas G. Purdie
    Nature Medicine, 2021, 27 : 999 - 1005
  • [43] FOLLOW-UP OF PROSTATE CANCER AFTER TREATMENT WITH CURATIVE INTENT: A SYSTEMATIC REVIEW OF LITERATURE
    Pernetti, Remigio
    Palmieri, Fabiano
    Voce, Salvatore
    Leoni, Maurizio
    ANTICANCER RESEARCH, 2015, 35 (06) : 3714 - 3714
  • [44] Kidney transplantation in prostate cancer patients after local therapy with curative intent: a systematic review
    Rumpff, C.
    Lieb, V.
    Wullich, B.
    Schiffer, M.
    Kunath, F.
    Apel, H.
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [45] Engaging with the National Optimal Lung Cancer Curative Intent Management Pathway: the Bristol experience
    Teh, E.
    Low, A.
    Casali, G.
    West, D.
    LUNG CANCER, 2019, 127 : S7 - S7
  • [46] COBALT THERAPY FOR PROSTATE CANCER - PRELIMINARY RESULTS
    CUKIER, J
    ROSEAUX, MD
    VANDERHA.D
    FAJBIJOW.S
    VACANT, J
    BEURTON, D
    JOURNAL D UROLOGIE ET DE NEPHROLOGIE, 1973, 79 (12BI): : 627 - 634
  • [47] Expectant management of stage A-1 (T1a) prostate cancer utilizing serum PSA levels: A preliminary report
    Loughlin, KR
    Renshaw, AA
    Kumar, S
    JOURNAL OF SURGICAL ONCOLOGY, 1999, 70 (01) : 49 - 53
  • [48] Expectant management with selective delayed intervention for favorable-risk prostate cancer
    Klotz, L
    PROSTATE AND RENAL CANCER, BENIGN PROSTATIC HYPERPLASIA, ERECTILE DYSFUNCTION AND BASIC RESEARCH: AND UPDATE, 2003, : 274 - 279
  • [49] American trends in expectant management utilization for prostate cancer from 2000 to 2009
    Maurice, Matthew J.
    Abouassaly, Robert
    Zhu, Hui
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (11-12): : E775 - E782
  • [50] Variations in the Metabolomic Profile Following Thoracic Surgery With Curative Intent in Lung Cancer. Preliminary Results From a Longitudinal Prospective Study (Promoter)
    Seijo, L.
    Pereira-Vega, A.
    Peces-Barba, G.
    Gotera Rive, C.
    Diaz-Olivares, I.
    Rodriguez, M.
    Padron, L.
    Blanco-Orozco, A.
    Lopez-Campos, J.
    Callejon-Leblic, B.
    Sanchez Espirilla, S.
    Gomez-Ariza, J.
    Garcia-Barrera, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207